How many drugs treat Tardive dyskinesia?

Drug Landscape tracks 2 marketed treatments for Tardive dyskinesia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Tardive dyskinesia?

Most recent: Ingrezza — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/tardive-dyskinesia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Tardive dyskinesia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tardive dyskinesia (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Tardive dyskinesia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Austedo	DEUTETRABENAZINE	Teva		Synaptic vesicular amine transporter		2017-01-01
Ingrezza	valbenazine	Neurocrine		Potassium voltage-gated channel subfamily H member 2, Synaptic vesicular amine transporter, Synaptic vesicular amine transporter

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-04-08 — Ingrezza · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Neurocrine · 1 drug in Tardive dyskinesia
Teva · 1 drug in Tardive dyskinesia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Tardive dyskinesia:

Cite this brief

Drug Landscape (2026). Tardive dyskinesia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/tardive-dyskinesia. Accessed 2026-06-10.

Tardive dyskinesia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing